Effective managed care organizations (MCOs) are increasing the scope and intensity of intervention for members with non-acute illnesses, chronic diseases, or high risk to ensure better outcomes and lower costs. This emerging model shifts the focus from cost of care to quality of care. Focused education, prevention, and screening programs may greatly improve quality of life, independence, and patient health. These interventions may also reduce overall healthcare costs. Osteoporosis is a condition that has excellent potential for pharmacist intervention.
Osteoporosis is a major public health threat for 28 million Americans, 80 percent of whom are women. A woman's risk of hip fracture is equal to her combined risk of breast, uterine, and ovarian cancer. In 1995 the direct medical costs for osteoporosis and the 1.5 million associated fractures was $13.8 billion -and the cost is expected to increase to more than $60 billion by 2020 if present trends continue.
C O N T I N U I N G E D U C AT I O N
steoporosis, which means "porous bones," is a skeletal disorder that compromises bone strength and predisposes an affected individual to fracture. 2 Although it affects both men and women, more than 40% of all women between the ages of 50 and 75 will experience an osteoporotic fracture of the neck, vertebra, proximal humerus, proximal tibia, or pelvis. Osteoporosis is often called "the silent disease" because its victims feel no pain as bones gradually and dangerously weaken. Bones become so weak and brittle that mild stress such as bending over, lifting a vacuum, or coughing can cause a fracture of the hip, spine, or wrist. Patients with osteoporosis have a corresponding increase in morbidity and mortality. Osteoporosis is currently one of the most under diagnosed and under treated medical disorders (Table 1, opposite) .
Osteoporosis is commonly considered a geriatric disease but its roots lie in childhood and adolescence when peak bone mass should be achieved. It can strike at any age, resulting in loss of height, severe back pain, and deformity (the classic curvature, dowager' s hump), and can impair walking ability. Hip fractures due to osteoporosis lead to immobility, loss of muscle tone, and decreased body strength. This can result in prolonged or permanent disability, an inability to care for oneself and complete dependence on others. Osteoporosis and its complications may even cause death; 12 to 20% of elderly people experiencing hip fractures die within a year. 3 However, osteoporosis is a disease that can be treated and prevented. In persons who are already suffering from osteoporosis, treatment can diminish additional bone loss and fractures.
II What is Bone?
Bone is living, growing tissue that is continually being broken down, resorbed and rebuilt (replaced by new bone) in a process called remodeling (or bone turnover). It has a collagen framework into which calcium phosphate is deposited. This combination of collagen and calcium makes bone strong yet flexible enough to withstand stress. Serving as the body' s calcium reservoir, bones and teeth contain more than 99% of the body' s stores of calcium. The remaining 1% of calcium circulates in the blood; this extracelluar calcium determines whether bone resorption will occur. When inadequate calcium intake causes serum calcium concentration to drop below levels needed for vital cell functions, calcium is leached from the bones.
Complex signals induce bone building and breakdown. Osteoblasts (cells that make and mineralize organic bone matrix) and osteoclasts (cells that resorb bone) are controlled 
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Bone formation outpaces resorption until peak bone mass (maximum bone density and strength) is reached by the middle of life' s third decade. It then plateaus for about 10 years, during which bone formation approximately equals bone resorption. Then, skeletal bone mass typically begins to decline slowly as removal of old bone exceeds formation of new bone. Normal rate of loss is approximately 0.3% to 0.5% per year. Inadequate amounts of vitamin D and calcium in the diet can accelerate the decline.
After menopause begins, women experience accelerated bone loss (which may be increased tenfold to the rate of 3% to 5% per year) for about five to seven years. Although decreases in bone mass are most rapid in the first five years after onset of menopause, loss persists into the postmenopausal years. Osteoporosis develops when bone resorption occurs too quickly or replacement occurs too slowly.
II Types of Osteoporosis
Osteoporosis is classified as primary or secondary, a simple classification scheme that reflects some physiological changes that occur with aging. Primary osteoporosis is further subdivided into three subtypes: Type I (postmenopausal), Type II (senile or involutional), and idiopathic. 4 Postmenopausal and senile osteoporosis pose the greatest health risk. Idiopathic osteoporosis occurs only rarely in children and young adults of both genders with normal gonadal function.
Primary Osteoporosis
Type I or postmenopausal osteoporosis (PMO) is accelerated bone loss (2% to 3% annually) related to estrogen deficiency associated with postmenopausal loss of ovarian function. It begins at menopause and, while the loss may continue for up to 20 years, it is most rapid during the first three to six years. Although six times more prevalent in women, it also occurs in men with low levels of serum testosterone or after castration and is directly related to gonadal function loss. Type I osteoporosis increases the risk for fractures in which trabecular bone is predominant, such as vertebral compression and distal forearm (Colles') fractures.
Type II (senile or involutional) osteoporosis is associated with normal aging and is the consequence of slow, progressive, constant bone loss (0.3% to 0.5% annually) over many years. Gradually, the number and activity of osteoblasts decline. This may be related to a reduced vitamin D synthesis or resistance to vitamin D activity. Twice as common in women as in men, Type II typically occurs in patients over 60 years of age. In those over 70, hip and vertebral fractures occur frequently. Older women may suffer from both Types I and II osteoporosis.
Secondary Osteoporosis
Secondary osteoporosis is bone loss caused by factors other than aging or estrogen deficit and accounts for only 5% of cases. 
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Osteoporosis Facts and Figures
It develops secondary to a medical condition or medications that affect bone metabolism. Its most common cause is use of oral steroid drugs. In these instances, the degree of bone loss often depends upon the steroid dose and treatment duration. Immobilization (from bed rest or in rare cases of prolonged weightlessness as found in space flight) also diminishes bone mass. Certain endocrinopathies associated with glucocorticoid excess and medical conditions described in Table 2 (page 59) may cause secondary osteoporosis. About 20% of fractures in this group are related to the medical conditions listed.
II Risk Factors
Certain factors increase an individual' s likelihood of developing this disease. Patients may have several risk factors or may develop osteoporosis with no identified risk factors. Gender -Women are at greater risk than men, experiencing fractures from osteoporosis about twice as often as men. Women typically have less bone tissue and tend to live longer than men, resulting in greater age-related bone loss. Sudden menopausal estrogen drop also accelerates bone loss. Correspondingly, men who have low levels of testosterone are at increased risk.
Age -Older people are at greater risk as bones become less dense and weaker with age.
Body size -Slender small-framed women are at greater risk. Ethnicity -Caucasian and Asian women are at highest risk. African-American and Hispanic women have a lower but significant risk for developing osteoporosis. Latino women and Caucasian women consume less calcium than the recommended dietary allowance in all age groups.
Family history -Susceptibility to fracture may be in part hereditary. People whose parents have a history of fractures often have reduced bone mass and may be at greater risk for fractures.
Lifestyle factors -Modifiable lifestyle choices that contribute to osteoporosis include diet low in calcium and Vitamin D, anorexia, a sedentary lifestyle or extended bed rest, cigarette smoking, and excess alcohol consumption.
Medications -The use of certain medications, such as longterm glucocorticoid or some anticonvulsants, can result in a loss of bone density and fractures. These are discussed below.
II Calcium's Role
Establishing the highest possible peak bone mass in youth and then working to prevent bone loss as one ages are the best ways to prevent osteoporosis. To reach optimal peak bone mass and continue building new bone tissue, several factors are involved.
Intake of Calcium. Adequate calcium intake is critical to achieve optimal peak bone mass and mitigate the rate of agerelated bone loss. Low calcium intake is associated with low bone mass, rapid bone loss, and high fracture rates.
The physiologic need for calcium changes with age. During rapid skeletal growth and pregnancy or breast feeding, the body' s demand for calcium is great. Older, postmenopausal women and older men also need more calcium. This increase may result from inadequate amounts of vitamin D, necessary for intestinal absorption of calcium.
National nutrition surveys consistently show that many people consume less than half the amount of calcium recommended to build and maintain healthy bones. For example, starting around the time of puberty, girls are less likely than adolescent boys to consume the recommended dietary intakes of calcium. Data from the National Health and Nutrition Examination Survey (NHANES III, 1988-94) demonstrate that approximately 90% of girls between the ages of 9 and 18 fail to consume the recommended calcium intake during crucial bone building years. 5 With age, the body absorbs calcium and other nutrients less efficiently. Older adults are more likely to have chronic medical problems and use medications that may impair calcium absorption. The most current information available recommends a daily calcium intake of 1,000 mg/day (approximately three 8 oz. glasses of milk) up to age 65 and 1,500 mg/day (approximately five 8 oz. glasses of milk) over age 65. Table 3 (above) shows the recommendations from NIH for daily calcium intake for women by age. Various experts recommend different calcium intake figures for different populations. Some supplementation schemes present slightly higher recommendations for postmenopausal women not on hormone replacement therapy and pregnant or lactating women.
Sources of Calcium
Studies indicate that dietary calcium is most effective. Low fat dairy products, such as milk, yogurt, cheese, and ice cream, are concentrated sources of calcium and are often fortified with Vitamin D. Some other food sources that are high in calcium include corn or 
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II Other Important Modifiable Factors
Vitamin D. Vitamin D plays an important role in calcium absorption and in bone health. Normally, as little as 10 minutes of sunlight daily promotes sufficient synthesis in the skin. But Vitamin D production decreases in the elderly, in people who are housebound, and during winter months. Individuals may require Vitamin D supplementation to ensure a daily intake of between 400 to 800 IU of Vitamin D, the amount found in one cup of fortified milk and most multivitamins. Besides sunshine, cod liver oil, multivitamins, liver, milk fortified with Vitamin D, and egg yolks are good sources of Vitamin D. Massive doses of Vitamin D supplements are not recommended.
Exercise. Like muscle, bone is living tissue that responds to exercise by becoming stronger. The best exercises for healthy bones are weight-bearing types that force the body to work against gravity: walking, hiking, jogging, stair-climbing, weight training, tennis, and dancing. Yet physicians or physical therapists should evaluate the exercise program or other normal activity of anyone diagnosed with osteoporosis to determine if twisting motions and impact movements need to be curtailed or moderated.
Smoking
Alcohol. Regular daily consumption of two to three ounces of alcohol may be damaging to the skeleton, even in young women and men. Heavy drinkers are more prone to bone loss and fractures due to poor nutrition as well as to an increased risk of falling.
Medications. Many medications can create conditions that reduce bone density. Moderate-to-high-dose glucocorticoid therapy is associated with loss of bone and increased risk of fracture. Generally, bone loss occurs in patients on oral doses of prednisone dosed at 7.5 mg per day or greater. Skeletal wasting is most rapid during the first six months of therapy and trabecular bone is affected to a greater degree than cortical bone. Injected corticosteroid can also produce this unwanted effect. Corticosteroid-induced osteoporosis is dose and durationdependent and alternate day dosing does not prevent it. 7, 8 Cumulative dose also affects bone loss severity. Whether there is a threshold dose of glucocorticoid below which bone loss does not occur is unknown. Patients taking glucocorticoids should increase their daily calcium intake to 1,500 mg and Vitamin D intake to 1000 IU and possibly take a bisphosphonate such as alendronate or risedronate.
Until autumn of 2001, scientists believed that low and medium doses of inhaled steroids did not effect bone metabolism or contribute to the development of osteoporosis. 7, 8 Research has shown that when inhaled steroids are combined with oral corticosteroid use or other risk factors, complications are more likely to occur. For example, in postmenopausal women bone density may be reduced by long-term exposure to inhaled corticosteroids. This effect is again related to treatment dose and duration. Recent research has shown that inhaled glucocorticoids lead to a dose-related loss of bone at the hip in premenopausal women. 9 Corticosteroid-induced osteoporosis may be mitigated by the use of estrogen replacement therapy or biphosphonate medications. 10 
II Detection
Up to 30% of a patient' s bone mass may be lost before osteoporosis is properly identified and diagnosed. In some cases tooth loss is an early indication of underlying bone loss. Often, the first sign of the disease is the onset of acute pain associated with a fracture. Proper identification of the cause of pain is cru-
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For best results with supplements, counsel patients to:
• Read the label to find the amount of elemental, or digestible, calcium per tablet. This helps determine how many tablets are needed for the appropriate dose.
• Look for the USP mark to make sure the supplement meets standards for purity and quality.
• Avoid taking calcium with high fiber meals or with bulk-forming laxatives. Fiber can reduce the amount of calcium the body absorbs.
• Avoid consuming more than 600mg of elemental calcium at one time. The body prefers small amounts of calcium throughout the day; two or three small doses improve absorption.
• Avoid taking more than 2000mg calcium daily to diminish potential adverse effects.
• Iron and calcium; a potential interaction blocks absorption.
• Drink plenty of fluids (six to eight glasses a day) to reduce risk of kidney stones.
• Avoid bone meal, oyster shell (source of some calcium carbonate), and dolomite as calcium supplements; they may contain toxic ingredients like lead. • Osteopenia: reduced bone mass due to inadequate osteoid synthesis; and • Osteoporosis: a skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk. Osteopenia is a risk factor regarded as a precondition to osteoporosis. Osteoporosis is the disorder. Osteoporosis can be effectively treated if it is detected before significant bone loss has occurred. Therefore, early detection is important. Selective screening of asymptomatic perimenopausal women to detect low bone mass is a cost-effective use of health-care resources. It is never too late to treat established osteopenia and osteoporosis.
Adapted from "The Lowdown on Lactose Intolerance," National Dairy Council, 1997
BMD Testing
While a medical work up to diagnose osteoporosis often includes a complete medical history, x-rays, and urine and blood tests, early signs of osteoporosis can be detected with a simple, painless bone density test (densitometry). A form of x-ray, the bone mineral density (BMD) test measures bone density in the spine, wrist, and/or hip (the most common sites of fractures due to osteoporosis). Some BMD tests measure bone in the heel or hand. Bone density tests predict fractures better than blood pressure predicts strokes or cholesterol predicts heart attacks. They also confirm diagnosis and determine the rate of bone loss if done at intervals of a year or more. BMD tests are quick, noninvasive, and accurate for detecting low bone density, diagnosing osteoporosis, and predicting risk of future fracturing. Patients can find the location of a bone density testing center nearest them by telephoning the National Osteoporosis Foundation helpline at (202) 223-2226 or checking the Web site at www.nof.org.
Currently, the most accurate, comprehensive, and fastest of these techniques is dual-energy x-ray absorptiometry (DEXA), which measures bone density throughout the body within two to four minutes. Density is measured by detecting how bones absorb photons (atomic particles with no charge) that are generated by very low-level x-rays. Physicians use a formula based on the results of these procedures to determine if bone density has deteriorated to the fracture threshold-the point where fractures will result from mild stress. Levels of spinal bone mineral density measuring 2.0 standard deviations or more below the mean reference population of young adult women are considered abnormal. The risk of fracture doubles with each standard deviation below peak adult bone mass.
Since 1998, the Sahara Clinical Bone Sonometer has been FDA approved to measure bone density by transmitting painless sound waves through the heel of the foot. The more dense the bone, the healthier it is, and the longer it takes for sound waves to pass through. The sonometer is a portable, inexpensive device that may make screening more accessible for everyone who is at risk for osteoporosis and it is the machine of choice for use in pharmacy settings. Although the sonometer is accurate enough for screening, it is not as sensitive a diagnostic tool as other methods such as the DEXA machine.
Biochemical Tests
Collagen is the major structural protein of bone. Urine tests known as collagen crosslinks can characterize the state of bone metabolism by detecting excessive bone breakdown or impaired reformation. Although not indicated for routine diagnosis of osteoporosis, these biochemical markers of bone remodeling help determine if treatment is needed or the effectiveness of treatment. High levels of deoxypyridonoline and C-telopeptide, chemicals produced when bone is broken down, indicate increased fracture risk.
Other biochemical crosslinks measure bone degradation by detecting a substance called N-telopeptide, which indicates bone loss (although it is not associated with increased fracture risk). Biochemical bone turnover markers complement rather than replace BMD measurements; estimate fracture risk; and document the need for intervention.
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The primary goal of screening is to identify osteopenia early so that individuals at risk achieve adequate peak bone mass prior to natural menopause and the subsequent age-related years of bone mineral loss. This is in contrast to the present approach which emphasizes detection and management of osteoporosis in postmenopausal and older women. For women, the path to bone health should begin before or at the time of the first menstrual period. Osteoporosis screening for men is not generally recommended because the disease is far less common in men than in women. However, men who are sedentary or have poor nutrition and unhealthy lifestyles are every bit as much at risk of bone loss as women.
By identifying women at high risk for osteoporosis at an early age, much can be done to enhance bone density through a healthy lifestyle with good nutrition, exercise, and the selective use of hormone and other anti-resorptive therapy. The National Osteoporosis Foundation (NOF) recommends that women have a bone density test if they are not taking estrogen and any of the following conditions apply: • If they use medications that can cause osteoporosis.
• If they have Type 1 diabetes, liver disease, kidney disease, or a family history of osteoporosis.
• If they experienced early menopause.
• If they are postmenopausal, older than age 50, and have at least one risk factor for osteoporosis. • If they are postmenopausal, older than age 65, and have never had a bone density test.
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II The Therapeutic Role of Medication
The desired outcomes of prescription medications to treat osteoporosis include preventing fractures, decreasing pain when present, and maintaining function. Although there is no cure for osteoporosis, pharmaceutical agents slow or stop further bone loss, increase bone density, and reduce fracture risk by inhibiting osteoclast activity. Currently, estrogen, bisphosphonates, calcitonin, and selective estrogen receptor modulators (SERMs) are FDA-approved for the treatment of PMO. Estrogen, raloxifene, risedronate, and alendronate are approved for prevention. An effective treatment regimen for osteoporosis should also include taking adequate amounts of calcium and Vitamin D in natural dietary or supplemental form, maintaining adequate body weight, and engaging in weight-bearing exercise. Many women incorrectly assume that prescription medications fight osteoporosis alone, an assumption that causes them to neglect their daily dietary intake needs and reduces the effectiveness of expensive medications. To fully benefit from therapy, women also require an adequate supply of calcium and Vitamin D to help preserve bone density. A recent National Institutes of Health consensus conference concluded that both are required for optimal treatment of osteoporosis. 2 According to a Physician Drug and Diagnostics Audit of 3,442 physicians conducted from April 1999 to April 2000, seven out of every 10 women who use one of the three common osteoporosis medications fail to consume adequate calcium.
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Estrogen. Post-menopausal reduction in bone density is well established. Estrogen replacement therapy (ERT) is traditionally the first-line therapy to prevent and treat osteoporosis. It is recommended both for postmenopausal women and for women at high risk. ERT doses ranging from 0.625 to 1.25 mg daily has been shown to reduce bone loss, increase bone density in both the spine and hip, and reduce the risk of hip and spinal fractures in postmenopausal women. It slows bone resorption. When estrogen is discontinued, rapid bone loss resumes.
ERT is most effective for the first five to 10 years after menopause but can slow bone loss when started later, even after age 70.
14 Estrogen replacement should also be considered by women who have experienced natural menopause and have multiple osteoporosis risk factors. ERT is especially recommended for women whose ovaries were removed before age 50.
Women who have an intact uterus should also take progestin in conjunction with estrogen to alleviate risk of endometrial cancer. Progestin given in conjunction with estrogen is called hormone replacement therapy or HRT.
HRT/ERT has been shown to have beneficial effects on the skeleton and on menopause symptoms such as hot flashes. Epidemiological studies of HRT indicate a 50% to 80% decrease in vertebral fractures and a 25% decrease in other fractures with five years of use and an anticipated 50% to 75% decrease in all fractures with ten or more years of use. 15 Both HRT and ERT can cause side effects including bloating, breast tenderness, cramping, irritability, depression, and sometimes spotting or a return of monthly periods for a few months or years. These effects may disappear over time or controlled by changing the dose, the dosage form, or the administration time.
Some of the known or suspected risks of ERT and HRT include the following:
Endometrial cancer. Unopposed estrogen therapy substantially increases risk of endometrial cancer, the third most common cancer in women in the United States. Of women with an intact uterus who receive ERT, approximately 12% to 40% percent will develop endometrial hyperplasia (incidence increases as therapy lengthens). Of this group, between 3% and 75% will develop endometrial cancer (the risk depends upon length of follow-up and severity of hyperplasia at time of diagnosis). 15 Addition of a progestin reduces the risk of endometrial cancer to that of women not taking hormones.
Breast cancer. The association between breast cancer and postmenopausal hormone replacement therapy is controversial. 16 Many practitioners believe that if the patient is not at high risk for breast cancer, she can safely use HRT or ERT. They assert that the benefits of this therapy outweigh the risks for most women, particularly those with a family history of osteoporosis.
Blood clots. Another possible risk of HRT, ERT, and the SERM raloxifene is significantly increased risk for blood clots for some women. The chance of developing clots is smaller for women not using these hormones or drugs.
HRT provides a significant benefit relative to its cost. However, compliance with HRT is typically poor due to fear of side effects, the fear of increased risk of breast or endometrial cancer, and perhaps treatment of a sometimes asymptomatic disease. Further, many women are uncomfortable with the adverse effects, such as vaginal bleeding, and bloating. Current research reports inconsistent findings that fuel confusion and concern. For instance, the American Cancer Society reported that postmenopausal women using estrogen had a substantially higher death rate than those who did not. According to the Cancer Prevention Study II, an analysis of data from researchers following the health status of 211,581 healthy postmenopausal women found that those who had used estrogen for 10 or more years had twice the risk of dying from ovarian cancer than 
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never-users. According to the report, the increased mortality risk persisted for up to 29 years after estrogen use was discontinued. 17 Nevertheless, there is now evidence that in elderly women, low dose estrogen may prevent bone loss with minimal adverse effect. Additionally, when adequate calcium, vitamin D, and exercise are used in combination with estrogen-based treatments, there are positive increases in bone density. 18 Each patient must consider ERT/HRT carefully. Postmenopausal women should be counseled individually to consider HRT or ERT. Most need help weighing risks and benefits. Counseling should stress that many years, or even decades of HRT may be necessary to substantially reduce fracture risk. Women who reject HRT should undergo BMD testing, and consider alternative treatment strategies.
Calcitonin. Calcitonin, a naturally occurring protein hormone involved in calcium regulation and bone metabolism, suppresses osteoclasts. Calcitonin-salmon, a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin (e.g., Calcimar), is closely related to the human hormone. It inhibits bone resorption and is FDA approved for treatment of PMO in women who are at least five years beyond menopause and have low bone mass. Calcitoninsalmon slows bone loss, increases spinal bone density, and, according to anecdotal reports, effectively relieves pain associated with vertebral collapse.
Calcitonin is currently available as an injection (taken 50 to 100 IU daily or every other day) or in a nasal spray (Miacalcin). The recommended daily dose of the nasal spray is one 200 IU spray to one nostril, alternating nostrils daily. The dose may be administered at any time during the day. Pain relief from calcitonin should begin within a few days, before significant effect on bone metabolism occurs. This effect is thought to be at least partly from stimulation of endogenous opioid release. For best results, therapy should be started soon after the fracture. Adequate calcium and vitamin D intake should be maintained during therapy.
While it does not affect other organs or systems in the body, injectable calcitonin may cause an allergic reaction and unpleasant side effects, including flushing of the face and hands, urinary frequency, nausea, and skin rash. Therefore, skin testing is recommended before treatment. Side effects reported with nasal administration are associated with the nose and include rhinitis and other nasal symptoms such as crusts, dryness, redness, sores, itching, runny nose, or tenderness.
Calcitonin reduces spinal fracture risk and may reduce hip fracture risk as well. However, its effect on stabilizing or increasing BMD and preventing fractures is lower than that of HRT or bisphosphonates. Its efficacy in women who already have fractures is poorly documented. Consequently, it is reserved as a possible alternative to estrogen therapy for women who refuse or cannot tolerate HRT and is an effective treatment for pain associated with vertebral compression fractures.
II Selective Estrogen Receptor Modulators
Raloxifene (Evista) is approved for the prevention and treatment of osteoporosis. From the class of compounds called selective estrogen receptor modulators (SERMs), raloxifene prevents bone loss (at the spine, hip, and total body) for postmenopausal women. Raloxifene' s effect on the spine does not appear to be as powerful as either ERT or bisphosphonates, but its effect on the hip and total body are comparable. Preliminary data shows that it reduces the risk of vertebral fracture by 40% -50% in women with osteoporosis.
In clinical studies, women taking raloxifene did not increase breast or uterine cancer risk. Additionally, raloxifene has been found to lower total cholesterol by about 7% and LDL ("bad") cholesterol by about 11%. It does not change HDL ("good") cholesterol.
Patients find raloxifene easy to take. Standard dosage is one 60mg tablet, once daily, at any time, with or without food. Reported side effects include hot flashes and deep vein thrombosis, the latter of which is comparable to estrogen therapy. While side effects are uncommon and usually do not require discontinuation, the return of hot flashes (occurring in up to 24.6% of women in trials) is unacceptable to some women.
Raloxifene is contraindicated in pregnant women or women who can become pregnant, are nursing, have severe liver problems, have had blood clots that required treatment, or become allergic to raloxifene. Patients should be counseled to call a healthcare provider immediately if they experience pain in the calves, leg swelling, sudden chest pain, shortness of breath, coughing up blood, or changes in vision. While taking raloxifene, concurrent cholesterol lowering agents or estrogen in any form are contraindicated. Concomitant administration of warfarin necessitates monitoring prothrombin times frequently for adjustments to warfarin dosage.
II Bisphosponates
Bisphosponates are a class of nonhormonal agents with a high affinity for bone inhibiting osteoclast function, decreasing bone resorption. Two agents, alendronate and risedronate, are currently approved for prevention and treatment of PMO.
Bisphosphonates are an important option for those women who meet BMD treatment criteria but are unable or unwilling to take HRT, including breast cancer survivors. Bisphosphonates may also be indicated when HRT treatment fails to improve BMD. In contrast with HRT, short-term alendronate therapy may be sufficient to reduce fracture risk. Longer-term use of alendronate appears to provide even greater protection from fractures. A recent trial found that alendronate therapy improved BMD more in menopausal women with osteoporosis when administered in combination with HRT than HRT administered alone.
Alendronate. Alendronate (Fosamax) is a bisphosphonate that has been approved for both the prevention and treatment of osteoporosis. In postmenopausal women with osteoporosis, alen-dronate reduces bone loss by slowing resorption. It increases bone density in both the spine and hip. Clinical trials indicate that treatment with alendronate reduces the incidence of fracture at the spine, hip, and wrist by 50% in patients with osteoporosis.
Possible side effects from alendronate may include abdominal or musculoskeletal pain, nausea, heartburn, or esophagitis. Alendronate is dosed 10mg daily for treatment and 5mg daily for prevention or a single 35mg weekly dosage. The dosing instructions present a challenge for some patients. Alendronate should be taken on an empty stomach and with a full glass (six to eight ounces) of plain water first thing in the morning to reduce risk of gastrointestinal symptoms (including chest pain, heartburn, painful or difficult swallowing and in rare instances esophageal ulceration). Even dosing with orange juice or coffee markedly reduces absorption. Thus, it is important to counsel the patient to remain upright for at least one-half hour or preferably one hour before taking the first food, beverage, or other medications of the day.
Risedronate. In April 2000, risedronate (Actonel) was approved by the FDA for the treatment and prevention of PMO and glucocorticoid-induced osteoporosis. Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism but with possibly fewer gastrointestinal symptoms than alendronate. It can reverse bone loss and help reduce fracture risk by stopping further bone loss and increasing bone mass.
Risedronate is not a hormone therefore it has neither the benefits nor risks of estrogen. Taken as directed, possible side effects include upset stomach, abdominal pain, constipation, diarrhea, gas, and headache. Its side effects generally are not sufficient to cause patients to stop taking the medication. Stomach or esophageal discomfort, difficult or painful swallowing, chest pain, or severe or persistent heartburn are reasons to discontinue the drug and contact a health care provider. It is contraindicated in patients with low blood calcium (hypocalcemia); an inability to sit or stand upright for 30 minutes; severe kidney disease; or an allergic reaction to the drug. Additionally, women who are pregnant or nursing or have severe kidney disease should talk to their physician before taking any bisphosphonate.
To help risendronate work correctly and avoid possible irritation of the esophagus, tablets should be administered first thing in the morning while the patient is in an upright position (sitting or standing) before having anything to eat or drink (other than water). Recommended dosage is one tablet swallowed whole (not chewed or dissolved) with six to eight ounces of plain water (not coffee, tea, or juice and especially not hot milk or other dairy products). Additionally, patients should not eat or drink anything (expect plain water) for 30 minutes after taking this drug. Certain foods, supplements, and medications can retard absorption; vitamins, calcium-, aluminum-, or magnesium-containing medications or antacids should be taken later in the day or at least 30 minutes after taking risendronate. If patients miss a dose, it should not be doubled at next dose.
II Conclusion
Osteoporosis is an orthopedic condition in which there is loss of bone mass and a breakdown in the microarchitecture of the bone. Its effects are costly both financially and in terms of quality of life. Pharmacists are positioned well to help patients determine if they are at risk, implement lifestyle changes, and adhere to drug therapy and daily calcium requirements. Managed care pharmacists can include detection and prevention programs to help initiate the adverse effects of this insidious disease.
